The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines

Oral Oncology

Volumn 50, Issue 2, 2014, Pages 113-119

  Mouawad, F ^a,b,c   Gros, A ^a,c   Rysman, B ^a,b,c   Bal Mahieu, C ^a   Bertheau, C ^a,c   Horn, S ^a,c   Sarrazin, T ^a   Lartigau, E ^a   Chevalier, D ^b,c   Bailly, C ^d   Lansiaux, A ^a,c   Meignan, S ^a,c  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Etoposide; F14512; Head and neck cancer; Ionizing radiations; Polyamine transport system; Targeted therapy; Topoisomerase II inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; F 14512; FLUORESCENT DYE; FLUOROURACIL; SPERMINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER LOCALIZATION; CARCINOMA CELL; CLONOGENIC ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; LARYNX CANCER; PHARYNX CANCER; PRIORITY JOURNAL; TONGUE CANCER;

ETOPOSIDE; F14512; HEAD AND NECK CANCER; IONIZING RADIATIONS; POLYAMINE TRANSPORT SYSTEM; TARGETED THERAPY; TOPOISOMERASE II INHIBITION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; LARYNGEAL NEOPLASMS; MICROSCOPY, CONFOCAL; PHARYNGEAL NEOPLASMS; PODOPHYLLOTOXIN; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84891829511     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.11.003     Document Type: Article

References (29)

1. N. Vigneswaran, J. Wu, A. Song, A. Annapragada, and W. Zacharias Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC) Exp Mol Pathol 90 2 2011 215 225
2. J.P. Pignon, J. Bourhis, C. Domenge, and L. Designe Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of chemotherapy on head and neck cancer Lancet 355 9208 2000 949 955
3. J.M. Barret, A. Kruczynski, S. Vispe, J.P. Annereau, V. Brel, and Y. Guminski et al. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system Cancer Res 68 23 2008 9845 9853
4. A. Kruczynski, I. Vandenberghe, A. Pillon, S. Pesnel, L. Goetsch, and J.M. Barret et al. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system Invest New Drugs 29 1 2011 9 21
5. A.E. Pegg Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy Cancer Res 48 4 1988 759 774
6. R.A. Casero Jr., and P.M. Woster Recent advances in the development of polyamine analogues as antitumor agents J Med Chem 52 15 2009 4551 4573
7. N. Seiler, J.G. Delcros, and J.P. Moulinoux Polyamine transport in mammalian cells. An update Int J Biochem Cell Biol 28 8 1996 843 861
8. A.C. Gentry, S.L. Pitts, M.J. Jablonsky, C. Bailly, D.E. Graves, and N. Osheroff Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage Biochemistry 50 15 2011 3240 3249
9. A. Kruczynski, A. Pillon, L. Creancier, I. Vandenberghe, B. Gomes, and V. Brel et al. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity Leukemia 2013
10. De Botton S, Berthon C, Bulabois C, Prebet T, Vey N, Chevallier P. F14512 a novel polyamine-vectorized anti-cancer drug targeting topoisomerase II in adults patients with acute myeloid leukemia (AML): results from a Phase 1 study. EHA 17th Congress, Amsterdam; 201214-17.
11. A. Khafif, V.A. Canfield, E.J. Syzek, and J.E. Medina Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck Am J Otolaryngol 24 1 2003 1 5
12. A. Prevost, J.C. Merol, P. Aime, K. Moutel, F. Roger-Liautaud, and S. Nasca et al. A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck Oncol Rep 14 3 2005 771 776
13. C. Gedlicka, J. Kornfehl, D. Turhani, M. Burian, and M. Formanek Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck Cancer Invest 24 3 2006 242 245
14. Y. Tao, E. Bardet, D. Rosine, F. Rolland, E. Bompas, and N. Daly-Schveitzer et al. Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02 Radiat Oncol 2013 840
15. E.S. Schweikhard, and C.M. Ziegler Amino acid secondary transporters: toward a common transport mechanism Curr Top Membr 2012 701 728
16. J.P. Annereau, V. Brel, C. Dumontet, Y. Guminski, T. Imbert, and M. Broussas et al. A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment Leuk Res 34 10 2010 1383 1389
17. J. Gioanni, J.L. Fischel, J.C. Lambert, F. Demard, C. Mazeau, and E. Zanghellini et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment Eur J Cancer Clin Oncol 24 9 1988 1445 1455
18. K.J. Svensson, J.E. Welch, P. Kucharzewska, P. Bengtson, M. Bjurberg, and S. Pahlman et al. Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase Cancer Res 68 22 2008 9291 9301
19. V. Brel, J.P. Annereau, S. Vispe, A. Kruczynski, C. Bailly, and N. Guilbaud Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II Biochem Pharmacol 82 12 2011 1843 1852
20. C. Ballot, M. Jendoubi, J. Kluza, A. Jonneaux, W. Laine, and P. Formstecher et al. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II Apoptosis 17 4 2012 364 376
21. Y. Guminski, M. Grousseaud, S. Cugnasse, V. Brel, J.P. Annereau, and S. Vispe et al. Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system Bioorg Med Chem Lett 19 9 2009 2474 2477
22. S. Chelouah, C. Monod-Wissler, C. Bailly, J.M. Barret, N. Guilbaud, and S. Vispe et al. An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II PLoS One 6 8 2011 e23597
23. P. Vaupel, and A. Mayer Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 2 2007 225 239
24. S. Yoshiba, D. Ito, T. Nagumo, T. Shirota, M. Hatori, and S. Shintani Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest Oral Oncol 45 2 2009 109 115
25. M.R. Posner, C.M. Norris, L.J. Wirth, D.M. Shin, K.J. Cullen, and E.W. Winquist et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation Ann Oncol 20 5 2009 921 927
26. Y. Pointreau, P. Garaud, S. Chapet, C. Sire, C. Tuchais, and J. Tortochaux et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation J Natl Cancer Inst 101 7 2009 498 506
27. R.H. Kolb, P.M. Greer, P.T. Cao, K.H. Cowan, and Y. Yan ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation PLoS One 7 11 2012 e50281
28. A. Bozec, A. Sudaka, N. Toussan, J.L. Fischel, M.C. Etienne-Grimaldi, and G. Milano Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model Ann Oncol 20 10 2009 1703 1707
29. A.H. Ree, T. Stokke, A. Bratland, S. Patzke, R.V. Nome, and S. Folkvord et al. DNA damage responses in cell cycle G2 phase and mitosis - tracking and targeting Anticancer Res 26 3A 2006 1909 1916